Co-diagnostics Newsroom

Co-Diagnostics Analyst Ratings

BenzingaAug 13 02:20

Hold Rating Maintained for Co-Diagnostics Amidst Revenue Growth and Development Progress

TipRanksAug 12 21:57

HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $2 Price Target

BenzingaJun 17 22:57

Co-Diagnostics Analyst Ratings

BenzingaJun 17 22:56

HC Wainwright & Co. : Maintain the Co-Diagnostics (CODX.US) rating, adjust from neutral to neutral, and adjust the target price from $2.50 to $2.00.

Zhitong FinanceMay 13 19:10

Co-Diagnostics Analyst Ratings

BenzingaMay 13 19:10

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2

BenzingaMay 13 19:10

Co-Diagnostics Analyst Ratings

BenzingaMar 15 18:50

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2.5

BenzingaMar 15 18:50

HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $3 Price Target

BenzingaDec 29, 2023 19:34

Co-Diagnostics Analyst Ratings

BenzingaDec 29, 2023 19:32

Analysts' Opinions Are Mixed on These Healthcare Stocks: Natera (NTRA) and Co-Diagnostics (CODX)

TipRanksDec 29, 2023 19:20

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Raises Price Target to $3

BenzingaNov 13, 2023 23:43

Co-Diagnostics Analyst Ratings

BenzingaNov 13, 2023 23:33

Hold Rating on Co-Diagnostics: Revenue Decline Offset by Grant, FDA Submission on the Horizon, and Strong Cash Position Amid Potential Risks

TipRanksNov 13, 2023 19:40

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2

BenzingaAug 14, 2023 18:46

Co-Diagnostics Analyst Ratings

BenzingaAug 14, 2023 18:46

Co-Diagnostics (CODX) Receives a Hold From H.C. Wainwright

TipRanksMay 15, 2023 18:25

HC Wainwright & Co. Downgrades Co-Diagnostics to Neutral, Lowers Price Target to $3

BenzingaMar 20, 2023 19:52

H.C. Wainwright Remains a Buy on Co-Diagnostics (CODX)

TipRanksFeb 23, 2023 20:31